Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse ... call a number or fill a form on our site. Our content is intended ...

Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET today to review its first quarter 2025 ...

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...

DUBLIN, May 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced its financial ...

With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the ...

Nearly 1.8 million eye drop cartons were recalled in the U.S. due to potential sterility issues, posing serious risks like infections, temporary vision loss, or irreversible blindness.

With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ for the ...

Generated $52.5 million in net revenue from sales of LUMRYZ, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since ...

Puma Biotechnology release its 1Q'25 earnings results on May 8 after markets closed and followed with a conference call to ...

However, he has not yet found the same form he showcased during his breakout in 2024, as his arsenal has not been performing as well to this point. As shared by Eno Sarris of The Athletic ...